{"grounding": "Cystic fibrosis (CF) is an inherited multisystemic disease that can cause progressive bronchiectasis, pancreatic endocrine and exocrine insufficiency, distal intestinal obstruction syndrome, liver dysfunction, and other disorders. Traditional therapies focused on the treatment or prevention of damage to each organ system with incremental modalities such as nebulized medications for the lungs, insulin for diabetes, and supplementation with pancreatic enzymes. However, the advent of highly effective modulator therapies that target specific cystic fibrosis transmembrane conductance regulator protein malformations resulting from individual genetic mutations has transformed the lives and prognosis for persons with CF.", "generated_text": "Cystic Fibrosis (CF) is a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, leading to impaired chloride and bicarbonate transport. Recent advancements in CF treatment have focused on CFTR modulators, which target the underlying defect by enhancing CFTR protein function. This review explores the development, efficacy, and limitations of CFTR modulator therapies, including correctors, potentiators, and combination treatments. By analyzing clinical trial data and real-world outcomes, we assess the impact of these therapies on lung function, quality of life, and survival rates in CF patients, highlighting the transformative potential of precision medicine in CF care.", "label": 1}